Early relapse for Multiple Myeloma patients undergoing single auto-SCT: A single center experience

Publication date: Available online 1 November 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Holly Lee, Peter Duggan, Ahsan Chaudhry, Paola Neri, Jason Tay, Fariborz Rashid-Kolvear, Nizar J. Bahlis, Victor H. Jimenez-Zepeda Multiple myeloma is a heterogeneous disease with diverse clinical courses and patient outcomes. While the introduction of novel agents (NA) has improved the overall survival (OS) of myeloma patients, reports have highlighted that there persists a subset of patients who undergo early relapse (ER) whose prognosis is significantly poorer than patients with longer therapy response. The purpose of this study was to understand the impact of ER on OS, and to identify other predictors of OS. We analyzed the outcomes of 257 patients undergoing novel agent based induction and single auto-SCT treatment at our center between 2010 and 2016. ER was found in 35 patients (13.6%), and this group had a higher percentage of high-risk cytogenetics (48.5% vs 23.3%, p=0.0001), lower percentage of ≥VGPR (51.4% vs 80.5%, p=0.001), and shorter median OS (17.8 months vs NR, p=0.0001) than the non-ER group. Multivariate analysis showed that the presence of ER, high-risk cytogenetics, and LDH >350 UI/L are independent prognosticators for OS (p<0.05). Our results demonstrate that ER is an important clinical indicator of patients at high risk. As applications of NA evolve, further studies are required to tailor therapy for this patient group. Te...

Source: Clinical Lymphoma Myeloma and Leukemia - November 19, 2017 Category: Cancer & Oncology Source Type: research